Industry
Biotechnology
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Loading...
Open
1.18
Mkt cap
20M
Volume
72K
High
1.19
P/E Ratio
-0.89
52-wk high
2.26
Low
1.15
Div yield
N/A
52-wk low
1.10
Portfolio Pulse from
November 05, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 5:33 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 11:28 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 9:12 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 3:07 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 9:23 pm
Portfolio Pulse from Avi Kapoor
April 17, 2024 | 12:21 pm
Portfolio Pulse from Benzinga Newsdesk
April 17, 2024 | 9:53 am
Portfolio Pulse from Benzinga Newsdesk
April 16, 2024 | 11:05 am
Portfolio Pulse from Benzinga Newsdesk
April 15, 2024 | 11:23 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.